drugset / Trial / NCT01781702

Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients

NCT01781702

Phase 3 Completed 120 enrolled Daewon Pharmaceutical Co., Ltd.
RandomizedSingle-groupDouble-blindSupportive care

Summary

A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. \& Celebrex Cap. for Comparative Evaluation of Safety \& Efficacy in Rheumatoid Arthritis Patients

Timeline

Start
2010-10
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified 200 mg
Subject Pelubiprofen Small molecule 30 mg

Indications